Skip to main
MCK

McKesson (MCK) Stock Forecast & Price Target

McKesson (MCK) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

McKesson is a well-established and diversified company, with a strong presence in the US and Canadian pharmaceutical markets. Their expansion into services and technology solutions allows them to diversify their revenue streams and adapt to the changing landscape of the healthcare industry. The company's strong partnerships, solid balance sheet, and expected revenue growth make it a promising investment option for those with a positive outlook on the healthcare sector.

Bears say

McKesson is facing various challenges in the pharmaceutical industry, such as declining coverage for certain drugs and potential biosimilar adoption, while also aiming to expand into higher-margin services and sustain growth through targeting gene therapy products and focusing on high-growth and complex categories. The company has a strong presence in the industry and has reached a settlement for ongoing litigation, but there are potential risks and limitations to their growth, such as changes in reimbursement and the distraction of a planned spin-off. Additionally, McKesson's distribution economics are dependent on contracts but have shown a history of generating operating leverage and improving efficiency.

McKesson (MCK) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of McKesson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About McKesson (MCK) Forecast

Analysts have given McKesson (MCK) a Buy based on their latest research and market trends.

According to 15 analysts, McKesson (MCK) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $947.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $947.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

McKesson (MCK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.